Prime-edited isogenic hiPSC-derived cardiomyocyte model of short QT syndrome type 3 reveals electrophysiological phenotypes and differential drug responses

Min Woo Kim

doi:10.1016/j.lfs.2026.124573

Prime-edited isogenic hiPSC-derived cardiomyocyte model of short QT syndrome type 3 reveals electrophysiological phenotypes and differential drug responses

2026-07-07

0

PRE

AI

M

Min Woo Kim

J

Jeong Hwan Park

M

Myeonghee Lee

S

Seul-Gi Lee

J

Jeong-Seop Oh

S

Shinhye Park

Y

Youngin Jeong

Y

Yoonseo Kim

H

Hyewon Shin

J

Jin Kim

C

C‐Yoon Kim *

H

Hyung Min Chung *

DOI：10.1016/j.lfs.2026.124573

Original

Original request for help

Save

Abstract

En 中文

Short QT syndrome (SQTS) is a genetically inherited autosomal dominant cardiac channelopathy associated with paroxysmal atrial and ventricular fibrillation, syncope, and sudden cardiac arrest. Although SQTS is a well-known arrhythmogenic disorder, no optimal therapies currently exist due to its rarity and the challenges associated with diagnosis. Rodent models and patient-derived induced pluripotent stem cell (iPSC) models have been used to evaluate potential drug effects, but physiological and genetic variability between species and individuals can limit their fidelity. To address these limitations, we generated an isogenic human iPSC (hiPSC) model by introducing the short QT syndrome type 3 (SQT3)-associated KCNJ2 mutation into a normal hiPSC line using the Prime Editing 7 (PE7) system and differentiating it into cardiomyocytes (CMs). Multi-electrode array (MEA) analysis confirmed shortened field potential duration (FPD), an in vitro correlate of the QT interval as an electrophysiological SQT3 phenotype, validating the model's relevance to SQT3. Quinidine produced a consistent FPD-prolonging effect in the isogenic hiPSC-CMs, recapitulating previous clinical observations in a small number of SQT1 patients and supporting the model's utility as a reliable in vitro surrogate for assessing therapeutic strategies. Additionally, chloroquine, a selected candidate that has not yet been clinically validated, was evaluated and found to prolong FPD and induce irregular spontaneous beats indicative of arrhythmia. Overall, these findings demonstrate the potential of isogenic hiPSC-based platforms for elucidating disease mechanisms in rare genetic arrhythmogenic disorders and advancing the identification of candidate therapeutic agents.

Keywords:

Human induced pluripotent stem cells

Prime editing

Isogenic disease model

KCNJ2

Short QT syndrome type 3

Inherited arrhythmia

Prime-edited isogenic hiPSC-derived cardiomyocyte model of short QT syndrome type 3 reveals electrophysiological phenotypes and differential drug responses

Abstract

Journal

Organization

Cited Papers

Citing Papers